SCHEMBL24576965

SCHEMBL24576965

NC(=O)c1cnn2cc(-c3cn[nH]c3)sc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHEK1 O14757 2/20 0.37
▸ JAK1 P23458 6/20 0.34
▸ JAK3 P52333 5/20 0.34
▸ STING1 Q86WV6 1/20 0.33
▸ CDC7 O00311 2/20 0.33
▸ DBF4 Q9UBU7 2/20 0.33
▸ CCNE1 P24864 1/20 0.33
▸ CDK2 P24941 1/20 0.33
▸ ROCK1 Q13464 1/20 0.33
▸ PTGS1 P23219 1/20 0.33
▸ PTGS2 P35354 1/20 0.33
▸ GPR35 Q9HC97 1/20 0.32
▸ PLK1 P53350 1/20 0.32
▸ CHEK2 O96017 1/20 0.32
▸ ABL1 P00519 1/20 0.32
▸ RIPK2 O43353 1/20 0.32
▸ MKNK1 Q9BUB5 1/20 0.32
▸ MKNK2 Q9HBH9 1/20 0.32
▸ JAK2 O60674 5/20 0.32
▸ AKT1 P31749 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL29759885 0.99 CHEK1 (0.37) CHEK1JAK1JAK3STING1CDC7
SCHEMBL24578202 0.86 CDC7 (0.35) CHEK1CDC7DBF4CCNE1CDK2
SCHEMBL24578221 0.82 RIPK2 (0.33) JAK1JAK3RIPK2JAK2TYK2
SCHEMBL29759773 0.81 JAK1 (0.40) JAK1JAK3PTGS1PTGS2RIPK2
SCHEMBL29760263 0.80 CDC7 (0.43) JAK1JAK3CDC7DBF4ROCK1
SCHEMBL24576870 0.78 MKNK1 (0.41) CHEK1JAK1JAK3MKNK1MKNK2
SCHEMBL30566577 0.78 RIPK2 (0.32) CHEK1JAK1JAK3PTGS1PTGS2
SCHEMBL30566568 0.78 JAK1 (0.35) JAK1JAK3RIPK2MKNK1MKNK2
SCHEMBL29759991 0.77 MKNK1 (0.46) JAK1JAK3MKNK1MKNK2JAK2
Hydrochloric Acid SCHEMBL30566474 0.77 MKNK1 (0.41) CHEK1JAK1JAK3MKNK1MKNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240109917-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2024-04-04 — — US claimed
EP-4267585-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS Actelion Pharmaceuticals Ltd (CH) 2023-11-01 — — EP disclosed
WO-2022136509-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2022-06-30 — — WO disclosed
WO-2022136509-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2022-06-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109917-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS PDGFRA, PDGFRB, ABL1 CHEK1 974/4885JAK1 42/4885JAK3 59/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback